A large panel of CD8 + T cell clones generated from peripheral blood lymphocytes (PBL) of healthy donors or human immunodeficiency virus (HIV)-infected individuals were assessed for both cytokine secretion profile and CD30 expression and release. The great majority of CD8 + T cell dones generated from healthy individuals showed the ability to produce interferon 3' (IFN-3'), but not interleukin 4 (IL-4), and none of them either expressed membrane CD30 or released substantial amounts of soluble CD30 (sCD30) in their supernatant. In contrast, high numbers of CD8 + T cell clones generated from HIV-infected individuals, which produced IL-4 (and IL-5) in addition to IFN-3' or IL-4 (and IL-5) alone, expressed membrane CD30 and released detectable amounts of sCD30 in their supernatants. Indeed, CD30 expression appeared to be positively correlated with the ability of CD8 + T cell clones to produce IL-4 and IL-5 and inversely correlated with their ability to produce IFN-% whereas no correlation between CD30 expression and production of IL-10 was observed. These data suggest that CD30 is a marker for CD8 + T cells that have switched to the production of type 2 helper cytokines.
C
D30 is a 120-kD surface antigen originally identified by the Ki-1 mAb developed against Hodgkin s and ReedSternberg (H-RS) cells (1). CD30 antigen expression was then found in various non-Hodgkin's lymphomas (2) , as well as on several virally transformed T-(HTLV I and II) and B-(EBV) cell lines (3, 4) . That CD30 plays a role in normal lymphoid interaction is suggested by its histological detection on a scanty population of lymphoid cells in reactive lymph nodes and by induced expression on purified T and B cells after lectin activation (5) . cDNA cloning studies demonstrated that CD30 belongs to the TNF/nerve growth factor (NGF) receptor family (6, 7) , whose ligand is a new membrane-bound cytokine sharing a number of structural and functional similarities with TNF (8) . At present, the physiological role of CD30 is unknown. In recent studies, however, we have demonstrated that CD30 is selectively expressed by human CD4 + T cells producing type 2 helper (Th2) cytokines (9) .
In this report we have asked whether the association between CD30 expression and the ability to produce Th2-type cytokines is restricted to the CD4 § T cell subset or also extends to CD8 + T lymphocytes. To answer this question we have analyzed large panels of CD8 + T cell clones generated from both normal donors and HIV-infected individuals.
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CD8 + T cell clones producing Th2-type cytokines, which are rare in normal subjects, can be indeed generated in large numbers from some HIV-infected individuals (10) . Results showed that CD8 + T cell clones producing IFN-3/but not IL-4 or IL-5 (Thl-like) neither expressed membrane CD30 nor released soluble CD30 (sCD30) in their supematants (SN), whereas both membrane CD30 and sCD30 are consistently found in human CD8 + T cells producing IL-4 and IL-5 (Th0-or Th2-1ike). Thus, CD30 expression appears to be a marker not only for CD4 § Th2 cells, but also CD8 + T cells that have switched to the production of Th2-type cytokines.
Materials and Methods
Patients. The study was performed in five HIV-l-infected patients and three HIV-l-seronegative healthy volunteers. According to the Centers for Disease Control (CDC) criteria (11) , three of the patients were classified in the Group IV Subgroup C-1 because two have suffered from Pneumoffstis carinii and one from ToxopIasma gondii infection; two in the Group IV Subgroup D (one with Kaposi's sarcoma and one with non-Hodgkin's lymphoma). Immunophenotyping of PBMC by flow cytometry revealed very low levels of CD4 + T cells (<50/#1) in all five HIV-l-infected patients but normal values in the three HIV-l-seronegative subjects (920, 840, and 1,100 cells/#l, respectively). Absolute values of CD8 § T cells were within normal values (ranging from 350 to 600 cells/#l) in both HIV-l-infected patients and healthy subjects. All patients and controls gave informed consent for the studies.
Reagents. PHA (Mountain View, CA). Anti-CD30 mAb (Ber-H2) was purchased by Dako (Glostrup, Denmark).
T Cell Cloning System. PBMC were obtained from the four HIV-l-infected patients and the two HIV-seronegative healthy volunteers after Ficoll-Hypaque gradient centrifugation, and T cells cloned according to a previously described technique that allows the clonal expansion of virtually every T cell regardless of its antigen specificity (10) . Briefly, PBMC were seeded under limiting dilution conditions (0.3 cells/well) in round-bottomed microwells containing l0 s irradiated allogeneic spleen cells (as feeder cells) and PHA (1% vol/vol) in a final volume of 0.2 ml RPMI 1640 medium supplemented with 2 mM t-glutamine, 2 x 10 -5 M 2-ME (complete medium) containing human recombinant II~2 (20 U/ml) and 10% FCS (Hyclone Laboratories, Logan, UT). Growing microcultures were then supplemented at weekly intervals with IL-2 (20 U/ml) and 10 s irradiated feeder cells.
Immunophenotyping ofT Cell Clones. Cell surface marker analysis of T cell clones was performed on a Cytoron Absolute cytofluorimeter (Ortho Pharmaceuticals, Raritan, NJ) by using fluoresceinated (FITC) or phycoerythrinated (PE) anti-CD3, anti-CD4, anti-CDS, anti-cff~-TCK, or anti-CD30, as described (9, 10) .
Assessment of Cytokine Secretion Profile of T Cell Clones.
The cytokine secretion profile of T cell clones was evaluated by stimulating 106 T cell blasts from each done in 1 ml complete medium with PMA plus anti-CD3 Ab, as reported elsewhere (10) .
After 24 h, culture supematants were collected and stored at -70~ until used. The determination of IFN-3, and Ib4 was performed by a commercial KIA (Centocor Inc., Malvern, PA) and a commercial ELISA (Quantikine; K & D Systems, Inc., Minneapolis, MN), respectively. ID5 and I1,-10 were quantified by in house-made capture ELISAs using anti-Ib5 or anti-Ibl0 mAb bound to microwell plates, and biotinylated anti-IL-5 or anti-Ibl0 mAbs (PharMingen, San Diego, CA) as revealing antibodies, respectively. T cell clone SN showing IFN-',/, ID4, Ib5, or IL-10 levels 5 SD over the mean levels in control SN derived from irradiated feeder cells alone were regarded as positive.
Assessment of sCD30, sCD30 was measured in the SN of CD8 § T cell clones stimulated for 24 h with PMA plus anti-CD3 mAb by a CD30 ELISA test kit (Dakopatts, Glostrup, Denmark), based on the use of two mAbs reacting with two different epitopes of the 88-kD soluble form of CD30 molecule. The standard curve was prepared from six sCD30 calibrators and the concentration of sCD30 in SN was determined by interpolation of values detected in duplicate samples. The detection limit of the assay was estimated to be 1 U/ml by determination of the mean absorbanee (-+ 2 SD) of 20 measurements of the 0 U/ml standard (12). 
Results
A total number of 144 CD8 § odB-TCR + T cell clones generated from three normal donors and of 243 CD8 + c~/3-TCR + T cell clones generated from five HIV-infected individuals were assessed for ability to produce IFN-3r and/or IL-4 in response to stimulation with PMA plus anti-CD3 mAb. As shown in Table 1 , 85% of CD8 + T cell clones generated from normal donors produced IFN-3/but not IL-4 (Thl-like), whereas the other 15% produced both IFN-3' and IL-4 (Th0-1ike). In contrast, only 43% of CD8 + T cell clones generated from HIV-infected individuals showed a Thllike profile, whereas 36% produced IL-4 in addition to IFN-y (Th0-1ike) and 21% produced IL-4 but not IFN-3' (Th2-1ike).
A number of randomly selected CD8 + T cell clones from both normal donors and HIV-infected individuals were then assessed for membrane CD30 expression (112 T cell clones) and sCD30 release (84 T cell clones). Thl-like CD8 + T cell clones showed low or undetectable expression of membrane CD30 and did not release sCD30, whereas CD30 expression was found in virtually all Th2-1ike CD8 + T cell clones. Th0-1ike CD8 + T cell clones showed an intermediate pattern of CD30 expression (Figs. 1 and 2) . Likewise, high proportions of both Th2-and Th0-1ike clones also produced substantial amounts of sCD30 in their supernatants (Fig. 2) . As shown in Fig. 3, CD30 expression was positively correlated with the ability of CD8 + T cell clones to produce IL-4 and IL-5 and inversely correlated with their ability to produce IFN-% whereas no correlation between the expression of CD30 and the ability of CD8 § clones to produce IL-10 was observed.
Discussion
In a recent study, we have shown that CD30, a member of the TNF receptor superfamily (6, 7) is selectively expressed by human CD4 + T cells producing Th2-type cytokines (9) . Here, we demonstrate that even on activated CD8 + T cells CD30 is selectively expressed by those producing Th2-type cytokines. In fact, we found an inverse correlation of CD30 expression with the production of IFN-~/and positive correlation with the production of IL-4 and IL-5 even on activated CD8 + T cells. No correlation was found between CD30 expression and production of IL-IO by CD8 + T cell clones. This finding is not surprising since IL-10 production in humans is not restricted to Th2 cells (13, 14) , as it is in the mouse (15) . Thus, these data strongly support the view that the expression of CD30 reflects and/or defines a selective differentiation and/or activation pathway of T cells (both CD4 + and CD8 § producing Th2-type cytokines. So far, however, the molecular mechanisms responsible for this association remain unclear.
We have previously demonstrated the presence of Th2-1ike CD8 + T cells showing B cell helper activity and reduced cytolytic potential in two HIV-infected patients with a Job's- dent of other prognostic parameters (12) . The present demonstration of high numbers of CD8 + Th2-1ike clones that express membrane CD30 and can release detectable amounts of sCD30 may provide a reasonable explanation for this finding. Whether elevated serum levels of sCD30 in HIV infection reflect cleavage of membrane CD30 on activated Th2-1ike (CD4 § and CD8 +) T and/or B cells or result from HIV-mediated apoptosis of both CD4 § and CD8 § T cells remains to be established. Whatever mechanism is the possible role of CD30 in the immunopathogenesis of HIV infection deserves further investigation.
